carbamates has been researched along with Viremia in 19 studies
Viremia: The presence of viruses in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Owing to the advent of pangenotypic direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) treatment, utilization of HCV-infected deceased donor kidneys with simplified genotyping/subtyping-free sofosbuvir/velpatasvir (SOF/VEL) treatment strategy is now becoming a promising strategy for expanding the organ donor pool." | 4.12 | Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China. ( Dai, H; Fang, C; Guo, Y; Hu, S; Lan, G; Liu, Q; Nie, M; Peng, F; Peng, L; Tan, L; Xie, X; Zhang, H; Zhong, M, 2022) |
| "Amprenavir (APV) is an HIV protease inhibitor (PI) used for the treatment of either naive or PI-experienced HIV-infected patients." | 3.72 | Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. ( Affolabi, D; Bossi, P; Bricaire, F; Calvez, V; Costagliola, D; Delaugerre, C; Katlama, C; Ktorza, N; Lamotte, C; Marcelin, AG; Mohand, HA; Peytavin, G; Voujon, D; Wirden, M, 2004) |
| " Adverse events (AEs) associated with the study medication occurred in 21% of patients." | 2.74 | Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. ( Luque, I; Mallolas, J; Pérez-Elias, MJ; Rodríguez-Alcántara, F; Sánchez-Conde, M; Soriano, V, 2009) |
| " The most common adverse events considered to be possibly drug related were nausea, rash, oral paresthesia, diarrhea, and fatigue." | 2.69 | A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. ( Antunes, F; Brown, DJ; Clumeck, N; Fetter, A; Haubrich, R; Kahl, L; Lang, W; Pagano, G; Richman, D; Schooley, R; Sereni, D; Stein, A; Thompson, M; van der Ende, ME, 1999) |
| " Importantly, adjustments to the immunosuppressant dosage were not required." | 1.42 | Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant. ( Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Papadopoulos-Köhn, A; Paul, A; Timm, J; Walker, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, H | 1 |
| Liu, Q | 1 |
| Hu, S | 1 |
| Zhong, M | 1 |
| Peng, F | 1 |
| Guo, Y | 1 |
| Fang, C | 1 |
| Nie, M | 1 |
| Tan, L | 1 |
| Dai, H | 1 |
| Xie, X | 1 |
| Peng, L | 1 |
| Lan, G | 1 |
| Terrault, NA | 1 |
| Burton, J | 1 |
| Ghobrial, M | 1 |
| Verna, E | 1 |
| Bayer, J | 1 |
| Klein, C | 1 |
| Victor, D | 1 |
| Mohan, S | 1 |
| Trotter, J | 1 |
| Dodge, J | 1 |
| Niemann, CU | 1 |
| Rubin, RA | 1 |
| Yu, ML | 1 |
| Huang, CF | 1 |
| Wei, YJ | 1 |
| Lin, WY | 1 |
| Lin, YH | 1 |
| Hsu, PY | 1 |
| Hsu, CT | 1 |
| Liu, TW | 1 |
| Lee, JJ | 1 |
| Niu, SW | 1 |
| Huang, JC | 1 |
| Hung, TS | 1 |
| Yeh, ML | 1 |
| Huang, CI | 1 |
| Liang, PC | 1 |
| Hsieh, MY | 1 |
| Chen, SC | 1 |
| Huang, JF | 1 |
| Chang, JM | 1 |
| Chiu, YW | 1 |
| Dai, CY | 1 |
| Hwang, SJ | 1 |
| Chuang, WL | 1 |
| Antón, MD | 1 |
| Polanco, A | 1 |
| Ferrando, I | 1 |
| Latorre, P | 1 |
| Pascual, A | 1 |
| Moreno Osset, E | 1 |
| Gottlieb, RL | 1 |
| Sam, T | 1 |
| Wada, SY | 1 |
| Trotter, JF | 1 |
| Asrani, SK | 1 |
| Lima, B | 1 |
| Joseph, SM | 1 |
| Gonzalez-Stawinski, GV | 1 |
| Hall, SA | 1 |
| Teraoka, Y | 1 |
| Uchida, T | 1 |
| Imamura, M | 1 |
| Hiraga, N | 1 |
| Osawa, M | 1 |
| Kan, H | 1 |
| Saito, Y | 1 |
| Tsuge, M | 1 |
| Abe-Chayama, H | 1 |
| Hayes, CN | 1 |
| Makokha, GN | 1 |
| Aikata, H | 1 |
| Miki, D | 1 |
| Ochi, H | 1 |
| Ishida, Y | 1 |
| Tateno, C | 1 |
| Chayama, K | 1 |
| Duerr, M | 1 |
| Schrezenmeier, EV | 1 |
| Lehner, LJ | 1 |
| Bergfeld, L | 1 |
| Glander, P | 1 |
| Marticorena Garcia, SR | 1 |
| Althoff, CE | 1 |
| Sack, I | 1 |
| Brakemeier, S | 1 |
| Eckardt, KU | 1 |
| Budde, K | 1 |
| Halleck, F | 1 |
| Herzer, K | 1 |
| Papadopoulos-Köhn, A | 1 |
| Walker, A | 1 |
| Achterfeld, A | 1 |
| Paul, A | 1 |
| Canbay, A | 1 |
| Timm, J | 1 |
| Gerken, G | 1 |
| Sankawa, Y | 1 |
| Pérez-Elias, MJ | 1 |
| Sánchez-Conde, M | 1 |
| Soriano, V | 1 |
| Mallolas, J | 1 |
| Luque, I | 1 |
| Rodríguez-Alcántara, F | 1 |
| Paulsen, D | 1 |
| Liao, Q | 1 |
| Fusco, G | 1 |
| St Clair, M | 1 |
| Shaefer, M | 1 |
| Ross, L | 1 |
| Bogner, JR | 1 |
| Eberle, J | 1 |
| Troendle, U | 1 |
| Goebel, FD | 1 |
| Marcelin, AG | 1 |
| Affolabi, D | 1 |
| Lamotte, C | 1 |
| Mohand, HA | 1 |
| Delaugerre, C | 1 |
| Wirden, M | 1 |
| Voujon, D | 1 |
| Bossi, P | 1 |
| Ktorza, N | 1 |
| Bricaire, F | 1 |
| Costagliola, D | 1 |
| Katlama, C | 1 |
| Peytavin, G | 1 |
| Calvez, V | 1 |
| Khanlou, H | 1 |
| Bhatti, L | 1 |
| Farthing, C | 1 |
| Haubrich, R | 1 |
| Thompson, M | 1 |
| Schooley, R | 1 |
| Lang, W | 1 |
| Stein, A | 1 |
| Sereni, D | 1 |
| van der Ende, ME | 1 |
| Antunes, F | 1 |
| Richman, D | 1 |
| Pagano, G | 1 |
| Kahl, L | 1 |
| Fetter, A | 1 |
| Brown, DJ | 1 |
| Clumeck, N | 1 |
| Rizzardi, GP | 1 |
| De Boer, RJ | 1 |
| Hoover, S | 1 |
| Tambussi, G | 1 |
| Chapuis, A | 1 |
| Halkic, N | 1 |
| Bart, PA | 1 |
| Miller, V | 1 |
| Staszewski, S | 1 |
| Notermans, DW | 1 |
| Perrin, L | 3 |
| Fox, CH | 1 |
| Lange, JM | 1 |
| Lazzarin, A | 1 |
| Pantaleo, G | 1 |
| Chang, HE | 1 |
| Tilling, R | 1 |
| Kinloch, S | 1 |
| Goh, LE | 1 |
| Cooper, D | 1 |
| Lampe, F | 1 |
| Zaunders, J | 1 |
| Hoen, B | 1 |
| Tsoukas, C | 1 |
| Andersson, J | 1 |
| Janossy, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Micro-elimination of Hepatitis C Virus Infection With Pan-genotypic DAA Regimen in Hepatitis C Highly Endemic and Contagious Community (ERASE-C)[NCT03891550] | Phase 3 | 135 participants (Anticipated) | Interventional | 2019-05-13 | Active, not recruiting | ||
| Comprehensive Surveillance of HCV Infecion in Uremics Under Maintenance Hemodialysis and Linking to Medical Care in Taiwan[NCT03803410] | 2,973 participants (Actual) | Observational | 2019-01-07 | Completed | |||
| A Phase II Trial to Evaluate the Safety and Efficacy of Induction Treatment With Lamivudine Plus Stavudine Plus Abacavir Plus Amprenavir/Ritonavir Followed by Supervised Treatment Interruption in Subjects With Acute HIV Infection or Recent Seroconversion[NCT00000940] | Phase 2 | 121 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for carbamates and Viremia
| Article | Year |
|---|---|
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Biopsy, Needle; Calcineurin Inhibitors; Carbam | 2019 |
[Complication sequelae prevented, morbidity decreased].
Topics: Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Py | 2015 |
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
Topics: Adult; Carbamates; CD4 Lymphocyte Count; Comorbidity; Drug Therapy, Combination; Female; Fever; Fura | 2009 |
Amprenavir in pre-treated patients: virological and immunological response in a cohort of 45 patients.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination | 2003 |
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protea | 1999 |
Therapeutic vaccination in primary HIV infection, the Quest trial.
Topics: AIDS Vaccines; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD8-Positive T-Ly | 2002 |
13 other studies available for carbamates and Viremia
| Article | Year |
|---|---|
Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chroni | 2022 |
Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Hetero | 2021 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy | 2021 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy | 2021 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy | 2021 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy | 2021 |
Hepatitis B reactivation in a patient with chronic hepatitis C treated with direct-acting antivirals.
Topics: Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Guani | 2018 |
Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Female; Heart Failure; Heart Transplantation | 2017 |
Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
Topics: Animals; Antiviral Agents; Benzazepines; Biomarkers; Carbamates; Drug Combinations; Drug Resistance, | 2018 |
Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus | 2015 |
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Topics: Carbamates; Cross-Sectional Studies; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV P | 2002 |
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Femal | 2004 |
Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Drug Adminis | 2006 |
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies | 2000 |
Conference looks at HIV drug resistance.
Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Inf | 1995 |
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
Topics: Adult; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Biomarkers; Carbamates; | 2002 |